Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Technik·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Technik·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

35% Chance
Polymarket

$10,095 Vol.

35% Chance
Polymarket

$10,095 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 evaluation agreement with Peptron grants only a non-exclusive, terminable license for internal R&D on the SmartDepot PLGA-based microsphere platform for long-acting peptide formulations, with the period extended through late 2026. No commercial licensing, technology transfer, or manufacturing rights deal has been announced despite the joint research committee’s work. Trader sentiment favoring “No” by October 7, 2026, at 66.5% reflects the absence of binding commitments, Lilly’s June 2025 exclusive FluidCrystal platform deal with Camurus for similar incretin therapies, and the remaining short window for a full upgrade. The evaluation’s easy termination clause and neutral progress updates further support the current market-implied odds.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$10,095
Enddatum
7. Okt. 2026
Markt eröffnet
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 evaluation agreement with Peptron grants only a non-exclusive, terminable license for internal R&D on the SmartDepot PLGA-based microsphere platform for long-acting peptide formulations, with the period extended through late 2026. No commercial licensing, technology transfer, or manufacturing rights deal has been announced despite the joint research committee’s work. Trader sentiment favoring “No” by October 7, 2026, at 66.5% reflects the absence of binding commitments, Lilly’s June 2025 exclusive FluidCrystal platform deal with Camurus for similar incretin therapies, and the remaining short window for a full upgrade. The evaluation’s easy termination clause and neutral progress updates further support the current market-implied odds.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$10,095
Enddatum
7. Okt. 2026
Markt eröffnet
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Eli Lilly licenses Peptron’s SmartDepot by October 7?" ist ein Prognosemarkt auf Polymarket, auf dem Händler „Ja"- oder „Nein"-Anteile kaufen und verkaufen, je nachdem, ob sie glauben, dass dieses Ereignis eintreten wird. Die aktuelle Wahrscheinlichkeit laut Community liegt bei 35% für „Yes". Wird „Ja" beispielsweise bei 35¢ gehandelt, schätzt der Markt die Wahrscheinlichkeit des Eintretens auf 35%. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen und Informationen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

Stand heute hat „Eli Lilly licenses Peptron’s SmartDepot by October 7?" ein Gesamthandelsvolumen von $10.1K generiert, seit der Markt am May 6, 2026 gestartet wurde. Dieses Aktivitätsniveau spiegelt starkes Engagement der Polymarket-Community wider und stellt sicher, dass die aktuellen Quoten von einem breiten Pool an Marktteilnehmern geprägt werden. Sie können Live-Preisbewegungen verfolgen und direkt auf dieser Seite auf jedes Ergebnis handeln.

Um auf „Eli Lilly licenses Peptron’s SmartDepot by October 7?" zu handeln, wählen Sie einfach, ob Sie glauben, dass die Antwort „Ja" oder „Nein" lautet. Jede Seite hat einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes widerspiegelt. Geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Wenn Sie „Ja"-Anteile kaufen und das Ergebnis als „Ja" aufgelöst wird, zahlt jeder Anteil $1 aus. Wird es als „Nein" aufgelöst, zahlen Ihre „Ja"-Anteile $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen, um einen Gewinn zu sichern oder einen Verlust zu begrenzen.

Die aktuelle Wahrscheinlichkeit für „Eli Lilly licenses Peptron’s SmartDepot by October 7?" liegt bei 35% für „Yes". Das bedeutet, die Polymarket-Community glaubt derzeit, dass eine Wahrscheinlichkeit von 35% besteht, dass dieses Ereignis eintritt. Diese Quoten werden in Echtzeit auf Basis tatsächlicher Handelsgeschäfte aktualisiert und liefern ein ständig aktualisiertes Signal dessen, was der Markt erwartet.

Die Auflösungsregeln für „Eli Lilly licenses Peptron’s SmartDepot by October 7?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.